Latest Earnings Results: Q2 '26
Estimated EPS
-$0.31
Reported EPS
-$0.22
Surprise
+28.54%
Estimated Rev
$25.86M
Reported Rev
$29.4M
Surprise
+13.69%
• Reported GAAP EPS of -$0.22 up 64.52% YoY • Reported revenue of $29.43M up 82.08% YoY • Alamar Biosciences expects full year 2026 revenue to be in the range of $116 million to $120 million, representing growth of 59% at the midpoint of the range compared to 2025.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.21 | -- | -- | N/A |
Q2 '26 | -$0.31 | -$0.22 | 28.54% | BEAT |
Q1 '26 | -$1.71 | -- | -- | N/A |